Frank Elsner III, a director at ACNB Corp (NASDAQ:ACNB), has recently made a purchase of the company’s common stock. According to the latest SEC filing, Elsner acquired approximately 5.49 shares on December 13, 2024, at a price of $45.55 per share, totaling $250. The purchase comes as ACNB’s stock has shown strong momentum, gaining nearly 45% over the past six months. Additionally, Elsner received 172.89 shares as part of a director compensation plan, valued at $7,874. Following these transactions, Elsner’s direct ownership in ACNB Corp stands at 27,149.9991 shares. The $390 million market cap company trades at a P/E ratio…
Author: user
Many asset owners are adopting net-zero objectives to manage their investment exposure to climate change risk. A net-zero investment objective aims to attain net-zero portfolio greenhouse gas (GHG) emissions by 2050, in line with the global goal of zero growth in real-world GHG emissions set by the Paris Agreement. Strategies to achieve a net-zero investment objective typically include reducing portfolio emissions to lower transition risk, investing in climate change solutions to capitalize on macro trend opportunities, and using engagement and advocacy to reduce systemic risks. Adding a net-zero objective to a traditional investment program presents challenges for asset owners because…
Investing.com — Baird cut its price target for Rivian Automotive Inc (NASDAQ:) to $16 from $18 given limited catalysts in 2025 and a weaker-than-expected demand environment for electric vehicles. The brokerage remains positive on Rivian’s brand and long-term prospects but expressed skepticism about near-term growth. Rivian’s Q3 results missed expectations, and its lowered production outlook has dampened its ability to offset fixed costs, Baird noted. “With the Volkswagen (ETR:) JV having recently closed and DOE funding announcement, which was a positive surprise, in the rearview, we see few catalysts in 2025 and expect shares to languish with EV sales, which may…
Investors are closely monitoring the company’s performance, as it navigates through the pressures of the biotech sector, which has been fraught with volatility. The 52-week low serves as a critical juncture for Sutro Biopharma (NASDAQ:), as market participants consider the company’s future prospects and potential for recovery. According to InvestingPro Fair Value analysis, the stock appears undervalued at current levels, though analysts anticipate sales decline in the current year. Discover comprehensive insights and 10+ additional ProTips with an InvestingPro subscription, including exclusive access to the detailed Pro Research Report for STRO. According to InvestingPro Fair Value analysis, the stock appears…
BRANFORD, Conn., December 18, 2024–(BUSINESS WIRE)–Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that the Compensation Committee of Quantum-Si’s Board of Directors has granted 46,666 restricted stock units (“RSUs”) to new employees under the Company’s previously adopted Quantum-Si Incorporated 2023 Inducement Equity Incentive Plan, as amended (the “2023 Inducement Plan”). The RSUs were granted as an inducement material to the new employees becoming an employee of Quantum-Si in accordance with Nasdaq Listing Rule 5635(c)(4). The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously…
In a turbulent market environment, Salarius Pharmaceuticals, Inc. (SLRX) stock has recorded a new 52-week low, dipping to $1.24. The micro-cap company, with a market value of just $1.82 million, has been navigating through a challenging phase. While maintaining a healthy current ratio of 4.09 and more cash than debt on its balance sheet, the company has seen its stock price significantly retreat from its 52-week high of $7.20. Investors have been cautious, reflecting in the stock’s performance with a stark 1-year change, showing a decline of -74.29%. This downturn highlights the volatility and the tough conditions faced by the…
In many ways, gauging the impact of the Federal Reserve lowering interest rates is like predicting when ice will thaw. We know something’s happening, but it takes a while, and there’s not much to look at. The Fed has cut short-term interest rates twice this fall, including a jumbo half-point discount to kick off the lower-rate season in September. Market watchers widely expect another quarter-point cut when the Fed meets Dec. 18. So what results can we see? When it comes to your money — checking and savings accounts, CDs, mortgages, and other loans — it often takes fractions to…
Skarie20 / Getty Images/iStockphoto Commitment to Our Readers GOBankingRates’ editorial team is committed to bringing you unbiased reviews and information. We use data-driven methodologies to evaluate financial products and services – our reviews and ratings are not influenced by advertisers. You can read more about our editorial guidelines and our products and services review methodology. 20 YearsHelping You Live Richer Trusted by Millions of Readers One of the fastest ways to grow your money is to make sure it is doing the earning for you, and not the other way around. If you don’t want to take higher risks with…
A man who has inherited a $550,000 IRA from his father looks over the account paperwork. SmartAsset and Yahoo Finance LLC may earn commission or revenue through links in the content below. If you inherit a tax-deferred retirement account, like an IRA or a 401(k), you’ll pay income taxes on the money when you withdraw it. Those withdrawals are subject to your marginal tax rate, not the original owners. This can reduce the value of your inheritance, potentially by quite a lot if you are in a high tax bracket. For example, say that you’re in the 32% tax bracket…
In a year marked by significant volatility, Teleflex Incorporated (NYSE:) stock has recorded a new 52-week low, dipping to $176.59. According to InvestingPro data, the company maintains a market capitalization of $8.2 billion and currently trades at a P/E ratio of 35.1x. This latest price level reflects a stark contrast to the company’s performance over the past year, with Teleflex witnessing a substantial 1-year change of -30.24%. Investors are closely monitoring the medical device company as it navigates through a challenging market environment, which has seen its stock price erode steadily from previous highs. Despite current challenges, InvestingPro analysis suggests…